MA-VERISTAT
29.3.2022 16:09:09 CEST | Business Wire | Press release
Veristat , a scientific-minded global clinical research organization (CRO), announced today the formalization of its Strategic Resourcing solution to offer clients the delivery of clinical development and regulatory expertise options fully tailored to their needs. Clients now have access to difficult-to-find experts dedicated to a specific requirement or function to meet their objectives and timelines.
Veristat has been providing demand-based resourcing on a less formalized basis for many years. With the Strategic Resourcing solution, a pipeline of discipline-specific expertise is available and ready to seamlessly integrate into dynamic clinical environments. Veristat resources support work across many disciplines including biostatistics, programming and data management, regulatory consulting, clinical operations including clinical monitoring, project management, site management, as well as medical affairs/safety, medical/regulatory writing, and pharmacovigilance.
“The biopharmaceutical industry is innovating and developing new treatments so rapidly that resourcing demands now outpace the current available talent pool,” commented Patrick Flanagan, Chief Executive Officer at Veristat. “This was a top industry challenge prior to the COVID-19 pandemic, and it remains a top challenge today. Sponsors expect their external partners to continually improve upon the ways in which they can help them achieve true scientific progress delivered with process agility. Our strategic resourcing option provides the necessary flexibility to support a client project in the manner they determine is best.”
Leading the initiative is Bill Donovan, Senior Vice President, Strategic Solutions at Veristat. An industry veteran, Bill has 20+ years of leadership experience partnering with global pharmaceutical and biotechnology companies to accelerate time-to-market results across all stages of clinical trials. Delivering quality specialty resourcing to meet a sponsor’s full spectrum of needs has been a vital component of customer engagements led by Donovan.
“Refining the ways in which we partner with clients to deliver higher efficiencies with accelerated timelines is an ongoing focus for us,” commented Donovan. “Providing drug developers with an agile and specialized resourcing model fully supports this objective. I am thrilled that Veristat has formalized our ability to enhance customer value by allowing sponsors to hire our experts when they cannot find the right talent to support study success.”
Veristat is currently working on projects to treat cancers, rare diseases, neurological disorders, infectious diseases and more. Treatments span vaccines, gene therapies, complex generics, immuno-therapies, and novel drugs. For many clients, Veristat becomes a sponsor’s project team. For others, Veristat provides the medical, scientific, clinical, and statistical expertise to help sponsors advance their therapy into and through the clinical development and regulatory approval process.
Veristat continues to offer its core end-to-end capabilities across the development continuum in both full service and functional service support capabilities as well. Learn more about Veristat’s Strategic Resourcing Solutions here: https://www.veristat.com/services/strategic-resourcing
About Veristat
Veristat , a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 27 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last 10 years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. Our bold thinking, focus, and extensive experience supporting complex drug development in rare and ultra-rare diseases significantly impacted the approval of 12% of the 2021 U.S. Food and Drug Administration (FDA) novel drugs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 10:00:00 CET | Press release
Plural’s largest raise to date: almost four times its €260m inaugural fund in 2022, and double its €500m second fund in 2024 All former founders and operators, Plural’s partners back founders early to build generational companies that compete globally from Europe Plural’s companies have raised over €3bn in follow-on capital in the last twelve months alone as European tech accelerates Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe
SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 09:36:00 CET | Press release
Initiative in Malawi, Burundi, Zambia and Zimbabwe will leverage SES satellite solutions to extend digital learning opportunities to 20,000-30,000 students and teachers. SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the futu
Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 09:00:00 CET | Press release
ActiveViam’s Atoti analytics will extend from Regnology Risk Hub to Regnology Supervisory Hub, so the regulated and their regulators can ask their own questions of granular data Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors fa
Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 08:06:00 CET | Press release
Crime Stoppers International asks the public to report illegal vapes and nicotine pouches as organised crime cashes in across Europe. Launched on the UN day against transnational organised crime: the criminals selling black market vapes and nicotine pouches also traffic fake medicine, illicit drugs and weapons. On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the
Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 08:00:00 CET | Press release
Backing late-stage life sciences companies through to clinical development, global expansion and commercialization. Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets. Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
